Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How To Transfer Clinical Trial Participants From Ukraine To EU Sites

Executive Summary

An EU expert group and a number of member state agencies have published advice on the practicalities of safely moving Ukrainian clinical trial subjects to sites in EU and European Economic Area countries.

You may also be interested in...



Ukraine War Could Spur Changes In The Clinical Trial Paradigm

Decentralized trials are a way to help displaced Ukrainians remain in studies and could encourage greater participation from individuals in other countries, those overseeing sites in Ukraine say.

Ukrainian Firm To Receive mRNA Tech Transfer From WHO Hub

The Ukrainian pharma firm Darnitsa, which is the latest firm to benefit from the WHO’s mRNA coronavirus vaccine initiative, says it is continuing production amidst the continuing Russian attacks on the country. Meanwhile, the European Medicines Agency has issued guidance for sponsors on methodological aspects of trials affected by the war.

EU Advises Use Of Pandemic Flexibilities For Trials In Ukraine

Amid the continuing conflict and the Russian shelling of hospitals in Ukraine, regulatory bodies, health authorities and clinical research organizations are issuing guidance on how to deal with the impact on clinical trials in both Ukraine and Russia.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS145996

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel